Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis

Bernard GR(2001)Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 699-709

Vincent JL(2003)Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis Crit Care Med 31 12-19

Laterre PF(2004)Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis Crit Care Med 32 2385-2391

LaRosa SP(2005)Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 353 1332-1341

Dhainaut JF(2003)Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial Crit Care Med 31 834-840

Lopez-Rodriguez A(2002)Is volume related to outcome in health care? A systematic review and methodologic critique of the literature Ann Intern Med 137 511-520

Steingrub JS(2003)Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality Stroke 34 1106-1113

Garber GE(2000)Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience JAMA 283 1151-1158

Helterbrand JD(2001)Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice CMAJ 165 311-317

Ely EW(2001)Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000 Arch Neurol 58 2009-2013

Bernard GR(2001)Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 699-709

Vincent JL(2003)Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis Crit Care Med 31 12-19

Laterre PF(2004)Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis Crit Care Med 32 2385-2391

LaRosa SP(2005)Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 353 1332-1341

Dhainaut JF(2003)Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial Crit Care Med 31 834-840

Lopez-Rodriguez A(2002)Is volume related to outcome in health care? A systematic review and methodologic critique of the literature Ann Intern Med 137 511-520

Steingrub JS(2003)Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality Stroke 34 1106-1113

Garber GE(2000)Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience JAMA 283 1151-1158

Helterbrand JD(2001)Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice CMAJ 165 311-317

Ely EW(2001)Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000 Arch Neurol 58 2009-2013